Paroxetine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Paroxetine: Ohdo syndrome and variants
One-Sentence Summary
Paroxetine is marketed in Canada for depressive and anxiety-related conditions, including major depressive disorder, obsessive-compulsive disorder, social phobia and post-traumatic stress disorder. The TxGNN model predicts it may be effective for Ohdo syndrome and variants, but this is a computational prediction only, with no clinical trials and no publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Ohdo syndrome and variants |
| TxGNN Prediction Score | 0.9911 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Paroxetine is generally known as a selective serotonin reuptake inhibitor (SSRI), and its efficacy in depression and anxiety disorders is well established. However, this general knowledge was not part of the compiled data and cannot be linked to the biology of Ohdo syndrome.
Ohdo syndrome and its variants (for example, the Say-Barber-Biesecker-Young-Simpson variant, associated with KAT6B variants) are rare neurodevelopmental disorders involving chromatin regulation, intellectual disability and characteristic facial features. No plausible pathway connecting serotonin reuptake inhibition to the underlying genetic defect has been identified from the available evidence.
The high prediction score (0.9911) reflects a model output only. Any mechanistic link would be speculative and would need independent validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Paroxetine has 20 valid single-ingredient authorizations in Canada and no cancelled ones. Dosage form and approved indication text were not available for these products. Five of the main authorizations are listed below.
| DIN | Product Name |
|---|---|
| 02248504 | PAXIL CR |
| 02240907 | APO-PAROXETINE |
| 02247751 | PMS-PAROXETINE |
| 02248914 | PRO-PAROXETINE |
| 02282852 | PAROXETINE |
Safety Considerations
- Conditions flagged in the knowledge graph as contraindication-related (from drug-disease relationships, not from label text): epilepsy, bipolar disorder, major affective disorder, liver disease, gallbladder disease, blood coagulation disease, neuroleptic malignant syndrome, inappropriate ADH syndrome, nephrogenic syndrome of inappropriate antidiuresis, serotonin syndrome, drug-induced akathisia.
- Drug Interactions: The query returned 100 interactions in total. Major-level interactions among those reviewed include:
- Bupropion
- Lorcaserin
- Diethylpropion
- Dolasetron
- Eliglustat
- Palonosetron
- Phentermine
Moderate-level examples include morphine, acetylsalicylic acid, cimetidine, clarithromycin, chlorpropamide, glimepiride and repaglinide. Aprepitant is a minor interaction.
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a model score. There are no clinical trials, no literature and no supported mechanistic link between serotonin reuptake inhibition and the genetic basis of Ohdo syndrome (evidence level L5).
To proceed, the following is needed:
- Mechanism of action data for paroxetine, and a scientifically plausible link to the pathophysiology of Ohdo syndrome (KAT6B-related chromatin regulation)
- Preclinical or literature evidence supporting any effect in this disease
- Health Canada package insert warnings and contraindications for safety screening
- Approved indication text and dosage form details for the Canadian licenses
- Assessment of route compatibility and the suitability of the safety profile for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.